CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 144 Insider Sale of Securities
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Planned sale President, COO & GM China sold 51,921 shares at an average $281.40 ($14,610,370)
- 144 Insider Sale of Securities
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Planned sale Director sold 41,760 shares at an average $261.28 ($10,911,252)
- 4 Open-market sale President, COO & GM China sold 0 shares
- 4 Gift Director gave 158,717 shares (gift)
- 4 Open-market sale Chief Executive Officer sold 41,210 shares at an average $242.67 ($10,000,483)
- 144/A Insider Sale of Securities
- 144 Insider Sale of Securities
- DEFA14A Proxy Proxy Materials
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- 4 Open-market sale Chief Executive Officer sold 58,590 shares at an average $249.13 ($14,596,247)
- 4 Open-market sale Chief Executive Officer sold 40,109 shares at an average $259.15 ($10,394,329)
- 4 Planned sale President, COO & GM China sold 51,921 shares at an average $261.59 ($13,581,905)
- 4 Grant or award Global Head of R&D acquired 69,251 shares (grant or award)
Page 14 of 64 · 1,278 filings